IRLAB Therapeutics AB (publ) - Asset Resilience Ratio
IRLAB Therapeutics AB (publ) (IRLAB-A) has an Asset Resilience Ratio of 59.23% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check IRLAB Therapeutics AB (publ) (IRLAB-A) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how IRLAB Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. See IRLAB Therapeutics AB (publ) (IRLAB-A) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down IRLAB Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IRLAB Therapeutics AB (publ) stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr81.86 Million | 59.23% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr81.86 Million | 59.23% |
Asset Resilience Insights
- Very High Liquidity: IRLAB Therapeutics AB (publ) maintains exceptional liquid asset reserves at 59.23% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
IRLAB Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio
Compare IRLAB Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for IRLAB Therapeutics AB (publ) (2016–2025)
The table below shows the annual Asset Resilience Ratio data for IRLAB Therapeutics AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 59.23% | Skr81.86 Million ≈ $8.81 Million |
Skr138.21 Million ≈ $14.87 Million |
+10.10pp |
| 2024-12-31 | 49.13% | Skr66.92 Million ≈ $7.20 Million |
Skr136.21 Million ≈ $14.66 Million |
-13.72pp |
| 2023-12-31 | 62.84% | Skr111.31 Million ≈ $11.98 Million |
Skr177.12 Million ≈ $19.06 Million |
-15.28pp |
| 2022-12-31 | 78.12% | Skr252.78 Million ≈ $27.20 Million |
Skr323.56 Million ≈ $34.82 Million |
-6.94pp |
| 2021-12-31 | 85.07% | Skr401.90 Million ≈ $43.25 Million |
Skr472.45 Million ≈ $50.84 Million |
+10.21pp |
| 2020-12-31 | 74.85% | Skr277.01 Million ≈ $29.81 Million |
Skr370.07 Million ≈ $39.83 Million |
+21.73pp |
| 2019-12-31 | 53.12% | Skr110.53 Million ≈ $11.89 Million |
Skr208.07 Million ≈ $22.39 Million |
-6.65pp |
| 2018-12-31 | 59.77% | Skr134.44 Million ≈ $14.47 Million |
Skr224.94 Million ≈ $24.21 Million |
+13.93pp |
| 2017-12-31 | 45.84% | Skr74.71 Million ≈ $8.04 Million |
Skr162.97 Million ≈ $17.54 Million |
+23.09pp |
| 2016-12-31 | 22.75% | Skr25.74 Million ≈ $2.77 Million |
Skr113.11 Million ≈ $12.17 Million |
-- |
About IRLAB Therapeutics AB (publ)
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pir… Read more